20
Jun
Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.The Mumbai-based drug firm had on Friday received manufacturing and marketing approval from the Drugs Controller General of India (DCGI). FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement. "This approval comes at a time when cases in India are spiralling like never before, putting a tremendous pressure on our healthcare system," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.The company hopes that the availability…